SCHEMBL6476702

SCHEMBL6476702

NN(CC1CCCCCCC1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.43
OPRD1 P41143 7/20 0.43
OPRK1 P41145 7/20 0.43
ESR1 P03372 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
PAX8 Q06710 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGES O14684 1/20 0.38
ALOX5 P09917 1/20 0.38
EPHX2 P34913 1/20 0.38
ATM Q13315 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CSF1R P07333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475795 1.00 OPRM1 (0.43) OPRM1OPRD1OPRK1ESR1NPC1
SCHEMBL6489498 0.98 OPRM1 (0.44) OPRM1OPRD1OPRK1ESR1NPC1
SCHEMBL6477206 0.90 OPRM1 (0.42) OPRM1OPRD1OPRK1ESR1KDM4E
SCHEMBL29116510 0.80 OPRM1 (0.46) OPRM1OPRD1OPRK1ESR1NPC1
SCHEMBL15998771 0.77 TRPV1 (0.46) OPRM1OPRD1OPRK1NPC1RAB9A
SCHEMBL21253881 0.76 OPRM1 (0.46) OPRM1OPRD1OPRK1ESR1NPC1
SCHEMBL3819538 0.76 OPRM1 (0.35) OPRM1OPRD1OPRK1NPC1RAB9A
SCHEMBL18658375 0.74 OPRM1 (0.52) OPRM1OPRD1OPRK1NPC1RAB9A
SCHEMBL1228424 0.73 TAAR1 (0.48) OPRM1OPRD1OPRK1ESR1NPC1
SCHEMBL24537293 0.72 KDM4E (0.45) OPRM1OPRD1OPRK1ESR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP OPRM1 2982/4885OPRD1 4047/4885OPRK1 4415/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP OPRM1 2982/4885OPRD1 4047/4885OPRK1 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.